BOT
Botanix Pharmaceuticals
Botanix Pharmaceuticals is an Australian clinical dermatology company focused on developing and commercializing innovative treatments for common skin diseases. Their lead product candidate is Sofdra, a potential treatment for primary axillary hyperhidrosis, and they are also developing other products for acne and atopic dermatitis.
Shorted
About
website
industry
address
Key Metrics
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Short Position Trends
Track bearish sentiment and short interest over time
Historical Price Data
View stock price movements, volume, and trading patterns
Industry & Focus
Company Overview
AI-generated company summary
Botanix Pharmaceuticals is an Australian clinical dermatology company focused on developing and commercializing innovative treatments for common skin diseases. Their lead product candidate is Sofdra, a potential treatment for primary axillary hyperhidrosis, and they are also developing other products for acne and atopic dermatitis.
Company History
Botanix Pharmaceuticals was founded to develop and commercialize novel treatments for skin diseases using a unique drug delivery system. The company has focused on cannabinoid-based therapies and has advanced several product candidates through clinical trials. Botanix is listed on the Australian Securities Exchange (ASX) under the ticker code BOT.
Competitive Advantages
Botanix's competitive advantages include: 1) a proprietary drug delivery system, Permetris™, which enhances the penetration of active ingredients into the skin; 2) a focus on cannabinoid-based therapies, which have shown promise in treating various skin conditions; and 3) a strong intellectual property portfolio protecting its product candidates and technologies.
Risk Factors
- •Clinical trial failures
- •Regulatory approval delays
- •Competition from existing treatments
Recent Developments
Last 6 months
No report(s) discovered, so recent developments cannot be accurately assessed.
Key People
Leadership team at Botanix Pharmaceuticals
Howie McKibbon
Executive Chairman
Howie McKibbon serves as the Executive Chairman of Botanix Pharmaceuticals.
Matt Callahan
CEO
Matt Callahan is the Chief Executive Officer of Botanix Pharmaceuticals.
Vince O'Neill
Company Secretary
Vince O'Neill serves as the Company Secretary of Botanix Pharmaceuticals.
Mr. Vincent P. Ippolito
MD & Executive Chairman
Dr. Howie McKibbon
Chief Executive Officer
Mr. Graeme Morissey
Chief Financial Officer
Mr. Chris Lesovitz
Chief Financial Officer of United States of America
Dr. Boris Meyerson Ph.D.
Chief Business Officer
Mr. David Morgan
Head of Corporate Affairs
Mr. Kevin Wojciechowski
Head of HCP Marketing & Sales Training